The FDA is encouraging sponsors to use innovative approaches to lessen reliance on on-site trial monitoring in draft guidance. Advances in technology could allow sponsors to monitor clinical trial quality without the need to visit sites frequently, and the US Food and drug Administration (FDA) has published draft guidance to encourage the shift.
